Rudi Pauwels

Rudi Pauwels (born 1960) is a Belgian pharmacologist. He studied pharmaceutical sciences at the Catholic University of Leuven, Belgium, and obtained a PhD with a dissertation on Development of New Anti-HIV Agents.
He did research on virology at the Rega Institute for Medical Research .[1] In 1994 he founded the Belgian biotech company Tibotec, together with his wife Carine Claeys, and in 1995 he co-founded Virco. At Tibotec he continued his work on HIV.[2] In 1999, he was elected as board member of the Flemish Institute for Biotechnology (VIB).

Rudi Pauwels is also the co-founder, director and CEO of a molecular diagnostic company, Biocartis SA, based in Parc Scientifique EPFL, Lausanne, Switzerland.

References

  1. ↑ Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J, et al., Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives, Nature. 1990 Feb 1;343(6257):470-4
  2. ↑ Vingerhoets J., Azijn H., Fransen E., De Baere I., Smeulders L., Jochmans D., Andries K., Pauwels R., de Béthune M-P., TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments, Journal of virology 2005;79(20):12773-82


This article is issued from Wikipedia - version of the Monday, March 14, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.